The GLP ‐1–Mitochondria Axis in Metabolic Aging

ABSTRACT

Metabolic aging underlies a cluster of chronic conditions—type 2 diabetes, cardiovascular disease, sarcopenia, and neurodegeneration—that account for a substantial share of global morbidity and mortality. A common feature is progressive mitochondrial dysfunction: impaired bioenergetics, disrupted quality control, and loss of metabolic resilience. Reduced mitochondrial DNA copy number in peripheral blood leukocytes is associated with cardiometabolic disease and mortality, but pre‐analytical variability, dependence on blood‐cell composition, and uncertain relationship to tissue‐level function mean it should be regarded as a candidate risk‐associated biomarker rather than a validated measure of mitochondrial integrity. Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs), developed for glycemic control, engage pathways implicated in mitochondrial biogenesis, dynamics, and mitophagy; whether these effects reflect direct receptor signaling, indirect consequences of weight loss, or secondary mediators such as interleukin‐6 remains debated and appears tissue‐dependent. In SELECT, semaglutide reduced major adverse cardiovascular events by 20% in obesity without diabetes, and a 2025 multi‐omic study in aged male mice found GLP‐1 RA treatment attenuated age‐associated molecular signatures despite only modest changes in food intake and body weight. No trial, however, has incorporated a prespecified mitochondrial endpoint, human mechanistic evidence remains limited, and access to these therapies remains uneven worldwide. Here we synthesize mechanistic, preclinical, and clinical evidence for a proposed GLP‐1–mitochondria axis, classify this evidence by receptor dependence and translational stage, distinguish disease‐specific treatment effects from evidence for aging modification, examine four major controversies, and outline a research and policy agenda for responsible, evidence‐graded development of GLP‐1‐based geroscience interventions.